Based on the Avidity Biosciences Inc stock forecast from 9 analysts, the average analyst target price for Avidity Biosciences Inc is USD 63.69 over the next 12 months. Avidity Biosciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Avidity Biosciences Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Avidity Biosciences Inc’s stock price was USD 31.82. Avidity Biosciences Inc’s stock price has changed by -2.06% over the past week, -26.43% over the past month and +245.31% over the last year.
No recent analyst target price found for Avidity Biosciences Inc
No recent average analyst rating found for Avidity Biosciences Inc
Company Overview Avidity Biosciences Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. Read Less
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 10...Read More
Frequently Asked Questions About Avidity Biosciences Inc (RNA) Stock
Based on ratings from 9 analysts Avidity Biosciences Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 13 buy, sell and hold ratings.
Unfortunately we do not have enough data on RNA's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for RNA is USD 63.69 over the next 12 months. The maximum analyst target price is USD 96 while the minimum anlayst target price is USD 41.
Unfortunately we do not have enough data on RNA's stock to indicate if its overvalued.
The last closing price of RNA's stock was USD 31.82.
The most recent market capitalization for RNA is USD 3.88B.
Based on targets from 9 analysts, the average taret price for RNA is projected at USD 63.69 over the next 12 months.
This means that RNA's stock price may go up by +100.16% over the next 12 months.
We can't find any ETFs which contains Avidity Biosciences Inc's stock.
As per our most recent records Avidity Biosciences Inc has 253 Employees.
Avidity Biosciences Inc's registered address is 10578 Science Center Drive, San Diego, CA, United States, 92121.
You can get more information about it from Avidity Biosciences Inc's website at https://www.aviditybiosciences.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Avidity Biosciences Inc (RNA) Stock
Based on ratings from 9 analysts Avidity Biosciences Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 13 buy, sell and hold ratings.
Unfortunately we do not have enough data on RNA's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for RNA is USD 63.69 over the next 12 months. The maximum analyst target price is USD 96 while the minimum anlayst target price is USD 41.
Unfortunately we do not have enough data on RNA's stock to indicate if its overvalued.
The last closing price of RNA's stock was USD 31.82.
The most recent market capitalization for RNA is USD 3.88B.
Based on targets from 9 analysts, the average taret price for RNA is projected at USD 63.69 over the next 12 months.
This means that RNA's stock price may go up by +100.16% over the next 12 months.
We can't find any ETFs which contains Avidity Biosciences Inc's stock.
As per our most recent records Avidity Biosciences Inc has 253 Employees.
Avidity Biosciences Inc's registered address is 10578 Science Center Drive, San Diego, CA, United States, 92121.
You can get more information about it from Avidity Biosciences Inc's website at https://www.aviditybiosciences.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RNA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
